A Review: Antibody-dependent Enhancement in COVID-19: The Not So Friendly Side of Antibodies

Overview

Journal Int J Immunopathol Pharmacol

Publisher Sage Publications

Specialties Allergy & Immunology
Pathology
Pharmacology

Date 2021 Oct 11

PMID 34632844

Citations 26

Authors

Gabriela Athziri Sanchez-Zuno

Monica Guadalupe Matuz-Flores

Guillermo Gonzalez-Estevez

Ferdinando Nicoletti

Francisco Javier Turrubiates-Hernandez

Katia Mangano

Jose Francisco Munoz-Valle

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependent enhancement phenomenon, better known as ADE. In this review, we provide an overview of SARS-CoV-2 infection as well as the immune response generated by the host. On the bases of this principle, we also describe what is known about the ADE phenomenon in various viral infections and its possible role as a limiting factor in the development of new vaccines and therapeutic strategies.

Citing Articles

Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.

Sun D, Lien T, Chang H Int J Mol Sci. 2025; 26(5).

PMID: 40076527 PMC: 11899886. DOI: 10.3390/ijms26051898.

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.

Padilla-Borquez D, Matuz-Flores M, Hernandez-Bello J, Rosas-Rodriguez J, Turrubiates-Hernandez F, Garcia-Arellano S Hum Vaccin Immunother. 2024; 20(1):2394265.

PMID: 39246041 PMC: 11385164. DOI: 10.1080/21645515.2024.2394265.

Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.

Rodriguez Rodriguez E, Nordvang R, Petersson M, Rendsvig J, Arendrup E, Fernandez Quintero M Protein Sci. 2024; 33(7):e5035.

PMID: 38923049 PMC: 11201815. DOI: 10.1002/pro.5035.

Parameter identifiability of a within-host SARS-CoV-2 epidemic model.

Yang J, Wu S, Li X, Wang X, Zhang X, Hou L Infect Dis Model. 2024; 9(3):975-994.

PMID: 38881537 PMC: 11180336. DOI: 10.1016/j.idm.2024.05.004.

References

Zhou Y, Chi J, Lv W, Wang Y . Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2020; 37(2):e3377. PMC: 7361201. DOI: 10.1002/dmrr.3377. View

Lokugamage K, Hage A, de Vries M, Valero-Jimenez A, Schindewolf C, Dittmann M . Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020; 94(23). PMC: 7654262. DOI: 10.1128/JVI.01410-20. View

Hur S . Double-Stranded RNA Sensors and Modulators in Innate Immunity. Annu Rev Immunol. 2019; 37:349-375. PMC: 7136661. DOI: 10.1146/annurev-immunol-042718-041356. View

Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Singh Malik Y . Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Front Immunol. 2018; 9:597. PMC: 5925603. DOI: 10.3389/fimmu.2018.00597. View

Zaichuk T, Nechipurenko Y, Adzhubey A, Onikienko S, Chereshnev V, Zainutdinov S . [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector]. Mol Biol (Mosk). 2020; 54(6):922-938. DOI: 10.31857/S0026898420060154. View

Stanifer M, Kee C, Cortese M, Zumaran C, Triana S, Mukenhirn M . Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells. Cell Rep. 2020; 32(1):107863. PMC: 7303637. DOI: 10.1016/j.celrep.2020.107863. View

Pang X, Zhang R, Cheng G . Progress towards understanding the pathogenesis of dengue hemorrhagic fever. Virol Sin. 2016; 32(1):16-22. PMC: 6702245. DOI: 10.1007/s12250-016-3855-9. View

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

10.

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

11.

Ricke D . Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol. 2021; 12:640093. PMC: 7943455. DOI: 10.3389/fimmu.2021.640093. View

12.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L . Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020; 221(11):1762-1769. PMC: 7184346. DOI: 10.1093/infdis/jiaa150. View

13.

Halstead S, Mahalingam S, Marovich M, Ubol S, Mosser D . Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10(10):712-22. PMC: 3057165. DOI: 10.1016/S1473-3099(10)70166-3. View

14.

Ali F, Kasry A, Amin M . The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Med Drug Discov. 2021; 10:100086. PMC: 7923861. DOI: 10.1016/j.medidd.2021.100086. View

15.

Lee W, Wheatley A, Kent S, DeKosky B . Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5(10):1185-1191. DOI: 10.1038/s41564-020-00789-5. View

16.

Xiang T, Liang B, Fang Y, Lu S, Li S, Wang H . Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. Front Immunol. 2021; 12:708523. PMC: 8242354. DOI: 10.3389/fimmu.2021.708523. View

17.

Arvin A, Fink K, Schmid M, Cathcart A, Spreafico R, Havenar-Daughton C . A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020; 584(7821):353-363. DOI: 10.1038/s41586-020-2538-8. View

18.

Temperton N, Chan P, Simmons G, Zambon M, Tedder R, Takeuchi Y . Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005; 11(3):411-6. PMC: 3298259. DOI: 10.3201/eid1103.040906. View

19.

Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G . Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 2020; 538:88-91. PMC: 7836704. DOI: 10.1016/j.bbrc.2020.10.102. View

20.

Fung S, Yuen K, Ye Z, Chan C, Jin D . A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020; 9(1):558-570. PMC: 7103735. DOI: 10.1080/22221751.2020.1736644. View